Patents Assigned to Shionogi & Co., Ltd.
-
Publication number: 20240217966Abstract: The present invention relates to a compound that has GLP-1 receptor agonist activity and is useful as a therapeutic or prophylactic agent for diseases associated with the GLP-1 receptor, or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt. Provided is a compound represented by formula (I): wherein A1 is C(R5) or the like, A2 is C(R6) or the like, A3 is C(R7) or the like, R5, R6, and R7 are each independently a hydrogen atom or the like, R1 is carboxy or the like, R2 is substituted or unsubstituted alkyl or the like, —X— is —O— or the like, the ring represented by: is a ring represented by: ?and the like wherein R10 is each independently halogen or the like, s is 0 or the like, R13 is each independently a hydrogen atom or the like, and R3 is substituted or unsubstituted aromatic carbocyclyl or the like, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 23, 2022Publication date: July 4, 2024Applicant: Shionogi & Co., Ltd.Inventors: Misato KITAMURA FUJIWARA, Shomitsu MAENO, Yuji NISHIURA
-
Patent number: 12024519Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: is or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.Type: GrantFiled: November 12, 2021Date of Patent: July 2, 2024Assignee: SHIONOGI & CO., LTD.Inventors: Kouhei Nodu, Yusuke Tateno, Kengo Masuda, Yuji Nishiura, Yoshikazu Sasaki
-
Publication number: 20240190975Abstract: The chimeric antigen receptor that recognizes CCR8 as an antigen of the present invention has cytotoxic activity against CCR8-expressing cells by being expressed in effector cells.Type: ApplicationFiled: March 31, 2022Publication date: June 13, 2024Applicants: Shionogi & Co., Ltd., Osaka UniversityInventors: Tetsuya Yoshida, Mai Yoshikawa, Miya Haruna, Morio Nagira, Koji Takahashi, Marina Hayashida, Hiroto Miwa, Yudai Sonoda, Naganari Ohkura, Shimon Sakaguchi, Hisashi Wada
-
Publication number: 20240182463Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.Type: ApplicationFiled: August 4, 2023Publication date: June 6, 2024Applicant: Shionogi & Co., Ltd.Inventors: Chika TAKAHASHI, Hidenori MIKAMIYAMA, Toshiyuki AKIYAMA, Kenji TOMITA, Yoshiyuki TAODA, Makoto KAWAI, Kosuke ANAN, Masayoshi MIYAGAWA, Naoyuki SUZUKI
-
Publication number: 20240180954Abstract: The present invention provides novel cationic lipids having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by Formula (I) or a pharmacologically acceptable salt thereof. In the Formula (I), R1 is a substituted or unsubstituted formula: (CH2)a—L1—(CH2)b—CH3; R2 is a substituted or unsubstituted C5-C20 alkyl group or a substituted or unsubstituted formula: —(CH2)c—L2—(CH2)a—CH3; L1 and L2 are each independently —C(?O)O—, —OC(?O)—, or —OC(?O)O—; a, b, c, and d are each independently an integer of at least 1, and the total of a and b and the total of c and d are each an integer of 5 to 25; R3 to R7 are each independently a hydrogen atom, a substituted or unsubstituted C1-C6 alkyl group, or the like; R8, R9, and R10 are each a hydrogen atom; the constituent atoms in the Formula (I) may form a ring; Z is —OC(?O)—, —C(?O)O—, —OC(?O)O—, or the like; and X is O or S.Type: ApplicationFiled: February 2, 2022Publication date: June 6, 2024Applicant: SHIONOGI & CO., LTD.Inventors: Akira KUGIMIYA, Jun NAKAMURA, Norikazu KURODA, Tetsuya TANINO, Atsushi HAYATA, Ippei MORITA, Shun KITAHATA
-
Publication number: 20240150853Abstract: The present invention provides a method for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity, and a kit for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity.Type: ApplicationFiled: February 25, 2022Publication date: May 9, 2024Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Shionogi & Co., Ltd.Inventors: Masaaki KITAJIMA, Ryo IWAMOTO, Yusaku MASAGO, Shin HAYASE, Yuka KATAYAMA ADACHI
-
Publication number: 20240148741Abstract: The present invention provides a formulation for oral administration, comprising a triazine derivative having virus proliferation inhibitory action.Type: ApplicationFiled: November 22, 2022Publication date: May 9, 2024Applicant: Shionogi & Co., Ltd.Inventors: Masato GOMI, Kensuke HORIUCHI, Masayuki MORIMOTO, Keisuke TAKAGAKI
-
Publication number: 20240092784Abstract: A condensed heterocyclic compound has a sepiapterin reductase inhibitory action and is particularly useful for treatment of a pain. The condensed heterocyclic compound represented by Formula (I) below (R1 represents a hydrocarbon group or the like; R2 and R3 represent a hydrogen atom or the like; R4, X, and Y represent defined substituents), a tautomer or a pharmaceutically acceptable salt of the compound, or a solvate of any of these.Type: ApplicationFiled: April 13, 2021Publication date: March 21, 2024Applicants: NISSAN CHEMICAL CORPORATION, SHIONOGI & CO., LTD.Inventors: Masahiro KAMAURA, Yusuke INABA, Yusuke SHINTANI, Yuki KUWANO, Moemi NAKAO, Hiroshi NAGAI, Noriyuki KUROSE, Kenji TAKAYA, Mado NAKAJIMA
-
Patent number: 11932696Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.Type: GrantFiled: December 28, 2020Date of Patent: March 19, 2024Assignees: SHIONOGI & CO., LTD., OSAKA UNIVERSITYInventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
-
Publication number: 20240083872Abstract: Provided are a compound having serotonin 5-HT2A receptor antagonism and/or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and/or inverse agonism comprising them.Type: ApplicationFiled: December 27, 2021Publication date: March 14, 2024Applicant: Shionogi & Co., Ltd.Inventor: Kenji NAKAHARA
-
Patent number: 11925648Abstract: The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance.Type: GrantFiled: October 22, 2020Date of Patent: March 12, 2024Assignee: SHIONOGI & CO., LTD.Inventors: Naoya Mizutani, Masayuki Morimoto, Maki Okabe, Masaaki Ito, Go Kimura
-
Patent number: 11911394Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.Type: GrantFiled: December 23, 2021Date of Patent: February 27, 2024Assignees: Shionogi & Co., Ltd.Inventors: Takeshi Noshi, Takahiro Noda, Ryu Yoshida, Takao Shishido, Kaoru Baba, Aeron C. Hurt, Leo Yi Yang Lee, Steffen Wildum, Klaus Kuhlbusch, Barry Clinch, Jan Michal Nebesky, Annabelle Lemenuel, Wendy S. Barclay, Jean-Eric Charoin, Yoshinori Ando
-
Patent number: 11897899Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 21, 2022Date of Patent: February 13, 2024Assignee: SHIONOGI & CO., LTD.Inventors: Hiroyuki Tobinaga, Koji Masuda, Masanao Inagaki, Manami Masuda
-
Patent number: 11883407Abstract: Provided is a pharmaceutical composition for treating chronic cough, which has substantially no side effects of taste disturbance. A pharmaceutical composition for treating chronic cough, comprising a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 4, 2019Date of Patent: January 30, 2024Assignee: SHIONOGI & CO., LTD.Inventors: Ryuta Tamano, Erika Kasai, Sayaka Miyazaki, Katsue Magari
-
Publication number: 20230382893Abstract: The present invention provides a compound represented by formula (I): wherein the dashed line indicates the presence or absence of a bond; R1 is carboxy or the like; L is substituted or unsubstituted non-aromatic carbocyclyldiyl or the like; R2 is substituted or unsubstituted alkyl; R3 is a hydrogen atom or the like; X is ?CRX— or ?N—; Y is ?CRY— or ?N—; U is —CRU? or —N?; V is —CRV? or —N?; W is ?CRW— or ?N—; ZA is —C? or —N—; ZB is —CR5R6— or the like; ZC is —CR7R8— or the like; RX, RY, RV and RW are each independently a hydrogen atom or the like; RU is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; R7 and R8 are each independently a hydrogen atom or the like; R4 is substituted or unsubstituted alkyloxy or the like, or a pharmaceutically acceptable salt thereof, having an antiviral activity; and a pharmaceutical composition comprising the same.Type: ApplicationFiled: October 27, 2021Publication date: November 30, 2023Applicants: Shionogi & Co., Ltd., UBE CorporationInventors: Azusa OKANO, Yusuke TATENO, Kouhei NODU, Shinji SUZUKI, Toshiyuki AKIYAMA, Masaaki MATOYAMA, Hirota AKAZA, Takashi FUKUDA
-
Patent number: 11814368Abstract: The present invention provides a compound exhibiting coronavirus 3 CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 29, 2022Date of Patent: November 14, 2023Assignees: SHIONOGI & CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Yuki Tachibana, Shota Uehara, Yuto Unoh, Kenji Nakahara, Yoshiyuki Taoda, Yukiko Yamatsu, Shigeru Ando, Michihito Sasaki
-
Patent number: 11807648Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.Type: GrantFiled: January 19, 2022Date of Patent: November 7, 2023Assignee: SHIONOGI & CO., LTD.Inventor: Setsuya Shibahara
-
Publication number: 20230321251Abstract: By administering a liposome formulation in which an antibacterial agent is bound to a liposome, in particular, a lipid-soluble side chain of the antibacterial agent is bound to a lipid of the liposome, and the antibacterial agent extends outward from a surface of the liposome, it is possible to provide a liposome formulation in which blood retention of an active ingredient is increased, an amount of the active ingredient taken by a reticuloendothelial system such as a liver is reduced, an amount of the active ingredient transferred into a kidney is reduced, and antibacterial activity can also be increased with little resistance.Type: ApplicationFiled: September 3, 2021Publication date: October 12, 2023Applicants: OSAKA UNIVERSITY, Shionogi & Co., Ltd.Inventors: Takashi MATSUZAKI, Hideki MAKI, Osamu YOSHIDA, Tomoyuki HOMMA
-
Publication number: 20230293036Abstract: An estimation system obtains brain wave measurement data and functional magnetic resonance imaging measurement data simultaneously measured from a subject, calculates first functional connectivity for each channel combination based on correlation between channels included in the brain wave measurement data, calculates second functional connectivity for each brain network based on correlation between regions of interest included in the functional magnetic resonance imaging measurement data, calculates a disorder-likelihood label by calculating a score representing disorder-likelihood to be estimated with the use of a plurality of second functional connectivities, and determines an estimation model for estimating disorder-likelihood based on prescribed first functional connectivity by machine learning using the first functional connectivity for each channel combination and the disorder-likelihood label.Type: ApplicationFiled: July 1, 2021Publication date: September 21, 2023Applicants: ADVANCED TELECOMMUNICATIONS RESEARCH INSTITUTE INTERNATIONAL, SHIONOGI & CO., LTD.Inventors: Takeshi OGAWA, Ryuta TAMANO, Motoaki KAWANABE, Mitsuo KAWATO
-
Publication number: 20230284983Abstract: There is provided a therapy selection support device that generates a discriminator (identifier) as a diagnostic marker or a classifier as a stratification marker through machine learning on the basis of measurement data on brain activities and that uses the discriminator or the classifier as a biomarker. A therapy selection support system 300a, 300b, 500 includes a clustering device 300b that executes stratification in which the results of measurement of brain functional connectivity correlation values acquired from a plurality of second subjects are divided into a plurality of clusters through a clustering process.Type: ApplicationFiled: July 15, 2021Publication date: September 14, 2023Applicants: ADVANCED TELECOMMUNICATIONS RESEARCH INSTITUTE INTERNATIONAL, HIROSHIMA UNIVERSITY, SHIONOGI & CO., LTD.Inventors: Yuto KASHIWAGI, Tomoki TOKUDA, Yuji TAKAHARA, Mitsuo KAWATO, Ayumu YAMASHITA, Okito YAMASHITA, Yuki SAKAI, Junichiro YOSHIMOTO, Go OKADA